Tigecycline
- Generic Name
- Tigecycline
- Brand Names
- Tygacil, Tigecycline Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39N5O8
- CAS Number
- 220620-09-7
- Unique Ingredient Identifier
- 70JE2N95KR
- Background
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
- Indication
For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, ...
- Associated Conditions
- Bacterial Infections, Community Acquired Pneumonia (CAP), Complicated Intra-Abdominal Infections (cIAIs), Complicated Skin and Skin Structure Infection
- Associated Therapies
- -
Antibiotic Therapy for Infectious Diseases
- Conditions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 300
- Registration Number
- NCT04937894
- Locations
- 🇨🇳
Wei Zhao, Jinan, Shandong, China
Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 60
- Registration Number
- NCT04489459
- Locations
- 🇪🇬
Qasr El Ainy, Cairo, Egypt
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 300
- Registration Number
- NCT04310930
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 90
- Registration Number
- NCT04208763
- Locations
- 🇮🇳
Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Menarini Group
- Target Recruit Count
- 268
- Registration Number
- NCT04042077
- Locations
- 🇮🇹
Hospital Agostino Gemelli, Roma, Italy
The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae
- Conditions
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Shanghai 10th People's Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03950544
- Locations
- 🇨🇳
Shanghai 10th people's hospital, Shanghai, Shanghai, China
Study of Tigecycline Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy(CRRT)
- Conditions
- Interventions
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02931526
- Locations
- 🇨🇳
Zhujiang Hospital,Southern Medical University, Guangzhou, Guangdong, China
Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical
- Conditions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2015-10-09
- Target Recruit Count
- 113
- Registration Number
- NCT02573064
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
- Conditions
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01970371
A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
- Conditions
- Interventions
- First Posted Date
- 2012-11-04
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 470
- Registration Number
- NCT01721408
- Locations
- 🇨🇳
Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
🇨🇳The Third People's Hospital of Hainan Province/department of general surgery, Sanya, Hainan, China
🇨🇳Jilin Province People's Hospital, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.